PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of jnnpsycJournal of Neurology, Neurosurgery and PsychiatryVisit this articleSubmit a manuscriptReceive email alertsContact usBMJ
 
J Neurol Neurosurg Psychiatry. 1987 June; 50(6): 766–774.
PMCID: PMC1032085

Decline in cerebral glucose utilisation and cognitive function with aging in Down's syndrome.

Abstract

The cerebral metabolic rate for glucose (CMRglc) was measured with positron emission tomography and [18F]2-fluoro-2-deoxy-D-glucose in 14 healthy subjects with Down's syndrome, 19 to 33 years old, and in six healthy Down's syndrome subjects over 35 years, two of whom were demented. Dementia was diagnosed from a history of mental deterioration, disorientation and hallucinations. All Down's syndrome subjects were trisomy 21 karyotype. CMRglc also was examined in 15 healthy men aged 20-35 years and in 20 healthy men aged 45-64 years. All subjects were at rest with eyes covered and ears plugged. Mean hemispheric CMRglc in the older Down's syndrome subjects was significantly less, by 23%, than in the young Down's syndrome group; statistically significant decreases in regional metabolism (rCMRglc) also were present in all lobar regions. Comparison of the younger control group with the older control group showed no difference in CMRglc or any rCMRglc (p greater than 0.05). Assessment of language, visuospatial ability, attention and memory showed significant reductions in test scores of the old as compared with the young Down's syndrome subjects. These results show that significant age differences in CMRglc and rCMRglc occur in Down's syndrome but not in healthy controls, and that, although only some older Down's syndrome subjects are demented, significant age reductions in neuropsychologic variables occur in all of them.

Full text

Full text is available as a scanned copy of the original print version. Get a printable copy (PDF file) of the complete article (1.3M), or click on a page image below to browse page by page. Links to PubMed are also available for Selected References.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.
  • Wisniewski KE, French JH, Rosen JF, Kozlowski PB, Tenner M, Wisniewski HM. Basal ganglia calcification (BGC) in Down's syndrome (DS)--another manifestation of premature aging. Ann N Y Acad Sci. 1982;396:179–189. [PubMed]
  • Ross MH, Galaburda AM, Kemper TL. Down's syndrome: is there a decreased population of neurons? Neurology. 1984 Jul;34(7):909–916. [PubMed]
  • Owens D, Dawson JC, Losin S. Alzheimer's disease in Down's syndrome. Am J Ment Defic. 1971 Mar;75(5):606–612. [PubMed]
  • Dalton AJ, Crapper DR, Schlotterer GR. Alzheimer's disease in Down's syndrome: visual retention deficits. Cortex. 1974 Dec;10(4):366–377. [PubMed]
  • Wisniewski K, Howe J, Williams DG, Wisniewski HM. Precocious aging and dementia in patients with Down's syndrome. Biol Psychiatry. 1978 Oct;13(5):619–627. [PubMed]
  • Thase ME, Liss L, Smeltzer D, Maloon J. Clinical evaluation of dementia in Down's syndrome: a preliminary report. J Ment Defic Res. 1982 Dec;26(Pt 4):239–244. [PubMed]
  • Thase ME, Tigner R, Smeltzer DJ, Liss L. Age-related neuropsychological deficits in Down's syndrome. Biol Psychiatry. 1984 Apr;19(4):571–585. [PubMed]
  • Wisniewski KE, Wisniewski HM, Wen GY. Occurrence of neuropathological changes and dementia of Alzheimer's disease in Down's syndrome. Ann Neurol. 1985 Mar;17(3):278–282. [PubMed]
  • Ropper AH, Williams RS. Relationship between plaques, tangles, and dementia in Down syndrome. Neurology. 1980 Jun;30(6):639–644. [PubMed]
  • Ball MJ, Nuttall K. Topography of neurofibrillary tangles and granulovacuoles in hippocampi of patients with Down's syndrome: quantitative comparison with normal ageing and Alzheimer's disease. Neuropathol Appl Neurobiol. 1981 Jan-Feb;7(1):13–20. [PubMed]
  • Mann DM, Yates PO, Marcyniuk B. Alzheimer's presenile dementia, senile dementia of Alzheimer type and Down's syndrome in middle age form an age related continuum of pathological changes. Neuropathol Appl Neurobiol. 1984 May-Jun;10(3):185–207. [PubMed]
  • Yates CM, Simpson J, Maloney AF, Gordon A, Reid AH. Alzheimer-like cholinergic deficiency in Down syndrome. Lancet. 1980 Nov 1;2(8201):979–979. [PubMed]
  • FAZEKAS JF, EHRMANTRAUT WR, SHEA JG, KLEH J. Cerebral hemodynamics and metabolism in mental deficiency. Neurology. 1958 Jul;8(7):558–560. [PubMed]
  • Lassen NA, Christensen S, Hoedt-Rasmussen K, Stewart BM. Cerebral oxygen consumption in Down's syndrome. Arch Neurol. 1966 Dec;15(6):595–602. [PubMed]
  • Risberg J. Regional cerebral blood flow measurements by 133Xe-inhalation: methodology and applications in neuropsychology and psychiatry. Brain Lang. 1980 Jan;9(1):9–34. [PubMed]
  • Schwartz M, Duara R, Haxby J, Grady C, White BJ, Kessler RM, Kay AD, Cutler NR, Rapoport SI. Down's syndrome in adults: brain metabolism. Science. 1983 Aug 19;221(4612):781–783. [PubMed]
  • Duara R, Margolin RA, Robertson-Tchabo EA, London ED, Schwartz M, Renfrew JW, Koziarz BJ, Sundaram M, Grady C, Moore AM, et al. Cerebral glucose utilization, as measured with positron emission tomography in 21 resting healthy men between the ages of 21 and 83 years. Brain. 1983 Sep;106(Pt 3):761–775. [PubMed]
  • Shiue CY, Salvadori PA, Wolf AP, Fowler JS, MacGregor RR. A new improved synthesis of 2-deoxy-2-[18F]fluoro-d-glucose from 18F-labeled acetyl hypofluorite. J Nucl Med. 1982 Oct;23(10):899–903. [PubMed]
  • Huang SC, Phelps ME, Hoffman EJ, Sideris K, Selin CJ, Kuhl DE. Noninvasive determination of local cerebral metabolic rate of glucose in man. Am J Physiol. 1980 Jan;238(1):E69–E82. [PubMed]
  • Haxby JV, Duara R, Grady CL, Cutler NR, Rapoport SI. Relations between neuropsychological and cerebral metabolic asymmetries in early Alzheimer's disease. J Cereb Blood Flow Metab. 1985 Jun;5(2):193–200. [PubMed]
  • Gath A. Cerebral degeneration in Down's syndrome. Dev Med Child Neurol. 1981 Dec;23(6):814–817. [PubMed]
  • Reiss S, Levitan GW, Szyszko J. Emotional disturbance and mental retardation: diagnostic overshadowing. Am J Ment Defic. 1982 May;86(6):567–574. [PubMed]
  • Miniszek NA. Development of Alzheimer disease in Down syndrome individuals. Am J Ment Defic. 1983 Jan;87(4):377–385. [PubMed]
  • KETY SS. Circulation and metabolism of the human brain in health and disease. Am J Med. 1950 Feb;8(2):205–217. [PubMed]
  • Mazziotta JC, Phelps ME, Carson RE, Kuhl DE. Tomographic mapping of human cerebral metabolism: sensory deprivation. Ann Neurol. 1982 Nov;12(5):435–444. [PubMed]
  • de Leon MJ, Ferris SH, George AE, Reisberg B, Christman DR, Kricheff II, Wolf AP. Computed tomography and positron emission transaxial tomography evaluations of normal aging and Alzheimer's disease. J Cereb Blood Flow Metab. 1983 Sep;3(3):391–394. [PubMed]
  • Friedland RP, Budinger TF, Ganz E, Yano Y, Mathis CA, Koss B, Ober BA, Huesman RH, Derenzo SE. Regional cerebral metabolic alterations in dementia of the Alzheimer type: positron emission tomography with [18F]fluorodeoxyglucose. J Comput Assist Tomogr. 1983 Aug;7(4):590–598. [PubMed]
  • Foster NL, Chase TN, Mansi L, Brooks R, Fedio P, Patronas NJ, Di Chiro G. Cortical abnormalities in Alzheimer's disease. Ann Neurol. 1984 Dec;16(6):649–654. [PubMed]
  • Yates CM, Ritchie IM, Simpson J, Maloney AF, Gordon A. Noradrenaline in Alzheimer-type dementia and Down syndrome. Lancet. 1981 Jul 4;2(8236):39–40. [PubMed]
  • Ball MJ, Nuttall K. Neurofibrillary tangles, granulovacuolar degeneration, and neuron loss in Down Syndrome: quantitative comparison with Alzheimer dementia. Ann Neurol. 1980 May;7(5):462–465. [PubMed]

Articles from Journal of Neurology, Neurosurgery, and Psychiatry are provided here courtesy of BMJ Publishing Group